Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value

$8.36−0.08 (-0.95%)

Close on Nov 13, 2026Market cap $237.62MP/E –Yield –

Arcturus Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Arcturus Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Arcturus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-7 reverse split on Nov 16, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing